Piramal Pharma likely to hit fresh highs as CDMO recovery lifts EBITDA, says Quest CIO
Piramal Pharma: The investment case, according to Quest CIO and portfolio manager Rakesh Vyas, rests on a fading destocking drag, a healthier growth trajectory in the core CDMO business.
Attribution
This digest is published with acknowledgment to Business Today. For the complete analysis, headnotes, and citations, please refer to the source.
Read on Business Today
